ABSTRACT Living cell therapies lack robust, reversible mechanisms for externally controlling therapeutic activity after administration, limiting their safety and clinical adaptability. Here we engineer a drug‐gated cellular immunotherapy platform in which T cells function as programmable factories that secrete two inac...
S. Luengo-Arias, Carmen Domínguez-Alonso, Ivana Zagorac et al.· Advancement of science· 0 citations
Abstract Background Immune checkpoint inhibitors have transformed non-small cell lung cancer (NSCLC) treatment. Understanding the tumor-immune interactions that dictate sensitivity to PD-1 blockade is essential for improving outcomes and optimizing immunotherapy personalization. Methods We performed compartment-specifi...
C. Fernández-Luna, J. Baena, A. Calles et al.· Journal for ImmunoTherapy of...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.